Inclusion Criteria : 
  -  Molecular confirmation of a pathogenic or likely pathogenic PCDH19 variant
  -  Failure to control seizures despite 2 or more anti - seizure medications
  -  12 seizures over a 12 - week period of primary seizure types prior to screening
  -  On a stable regimen of anti - seizure treatments ( Vagus nerve stimulator , ketogenic diet , and modified Atkins diet should be unchanged for 3 months prior to screening ) 
Exclusion Criteria : 
  -  Previous exposure to ganaxolone
  -  > 8 consecutive weeks of seizure freedom during the 12 weeks prior to screening
  -  Concurrent use of strong inducers or inhibitors of CYP3A4 / 5 / 7 is not permitted
  -  Use of tetrahydrocannabinol ( THC ) or non - approved cannabidiol ( CBD ) is prohibited during the double - blind phase
  -  Exposure to any other investigational drug within 30 days or fewer than 5 half - lives prior to screening